TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03543501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound imaging feedback
Description: Participants will be taught about the anatomy of abdominal wall muscles and the general functioning of RUSI (5 mins). Then, they will be invited to take the supine position, knees flexed. The feedback will consist of an ultrasound image transmitted to a brightness (B)-mode. Participants will receive the necessary education to understand the image and the desired recruitment according to a standardized protocol. They will then be asked to perform 15 contractions held 10 seconds of the TrA with a visible thickening of the TrA on the RUSI monitor exceeding the measurement at rest (visible on the monitor). Forty-five seconds rest will be allowed between each contraction to avoid fatigue. Participants will have to watch the RUSI monitor during the 15 tests.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBU feedback
Description: Participants will receive the same instruction on the anatomy of abdominal wall muscles and general information about the PBU device. They will be invited to take the same position as for the RUSI group (supine, knees flexed). The feedback will be to visualize the intensity of pressure on the dial of a STABILIZER PBU (Chattanooga Group, Hixon, TN). Participants will receive the education necessary to understand the tool and the desired recruitment according to a standardized protocol. They will then be asked to perform 15 contractions of the TrA with a duration of 10 seconds while maintaining the constant pressure at 40 mmHg ± 2 mmHg. Forty-five seconds of rest will be allocated between each contraction. Participants will have to watch the PBU dial during the 15 tests.
Study: NCT02612753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: improvement of language for aphasics patients
Description: Aphasics patients receive active stimulation during SLT

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: improvement of language for aphasics patients
Description: Aphasics patients receive active stimulation during SLT

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Aphasics patients control receive sham stimulation during SLT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCs
Study: NCT05742737

Intervention type: OTHER
Intervention: Frailty Index
Description: The mFI-5 scoring system used in the current study was developed by Saxton and Velanovich by comparing the five variables in the original CSHA-FI with NSQIP database

Intervention type: OTHER
Intervention: Frailty Index
Description: The mFI-5 scoring system used in the current study was developed by Saxton and Velanovich by comparing the five variables in the original CSHA-FI with NSQIP database
Study: NCT03450967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab Plus Tremelimumab
Description: Durvalumab 1500mg plus tremelimumab 75mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination until progression.).
Study: NCT01516593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Phase
Description: * dd -2 to 1: Methylprednisolone~* dd 0-1, Cyclophosphamide, associated on day 0 with Vincristine~* dd 2, Rituximab~* dd 7, Methotrexate~* dd 14, Rituximab~* dd 15, Etoposide~* dd 21, Methotrexate~* dd 29, Rituximab and Doxorubicin~* dd 36, Rituximab and VCR~At the end of this induction phase, subsequent treatment will be performed according to the objective response:~1. pts in CR: consolidation phase followed by bulky site irradiation~2. pts in PR: consolidation phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation~3. pts with SD after induction or PD during or after induction: intensification phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation Phase (on day +50)
Description: * dd 1-2: cytarabine twice a day~* dd 3 and 11: rituximab~* dd 11-13: leukapheresis for PBPC collection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensification phase
Description: 1. One or two courses of R-IVAC or R-ICE chemoimmunotherapy regimen, every three weeks as debulking.~2. CTX (dd 1) associated with rituximab on dd 3 and 10, followed by PBPC collection (dd 11-13);~3. AraC every 12 hours for four days (dd -5 to -2) supported by reinfusion of CD34+ cells (dd 0), rituximab infusion (dd -1 and +11) and second in-vivo purged PBPC collection (if needed).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEAM conditioning
Description: BCNU on dd 1; VP-16 every 12 hours on dd 2-5 and araC every 12 hours on dd 2-5; melphalan on dd 6, followed by the reinfusion of CD34+ cells

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Consolidation radiotherapy
Description: At the end of the whole program, patients will be evaluated for involved-field irradiation with 6-10 MeV photons and a dose of 36 Gy (2 Gy/d, five fractions a week). Three subgroups of patients will be considered for radiotherapy
Study: NCT02132013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention SUBLIME
Description: Intervention: dietary sodium restriction supported by 2 group meetings, structured self-regulation computer program, e-coaching.
Study: NCT01834989

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04046913

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dietary education
Description: Intervention: Low food additive diet. Control: Habitual food additive diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary education
Description: Intervention: Low food additive diet. Control: Habitual food additive diet
Study: NCT00242502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin)
Description: 10 mg/kg IV every 14 days, repeat cycle every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg orally every day continuous dosing, repeat cycle every 28 days
Study: NCT04006587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: incentive spirometer
Description: patients were instructed how to use the IS in a seated or semi-seated position, and to maintain sustained maximal inspiration for 3-5 seconds before exhalation, ten times per hour, and for at least eight hours a day.
Study: NCT00933452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: 30mg, oral administer; step 1: single dose; step 2: multiple dose, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: 15mg, oral administer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: 60mg, oral administer; step 1: generic duloxetine; step 2: Innovator duloxetine
Study: NCT00195104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide (Tricenox)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study: NCT03182049

Intervention type: PROCEDURE
Intervention: Airway assessment
Description: Airway Specialist (Otolaryngology, Pulmonology, Thoracic Surgery), assess clinical location and degree of airway compromise, glottic mobility, and sinonasal disease.

Intervention type: PROCEDURE
Intervention: Rheumatology assessment
Description: Clinically assess systemic function (renal/pulmonary ect), biochemical profile (routine labs), neurocognitive function, and completing entry BVAS tool.
Study: NCT04237597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877
Description: K-877 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSG452
Description: CSG452 tablets
Study: NCT02516761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-impact aerobic exercise combined with music therapy
Description: Intervention consists in working the muscles which are mostly affected by fibromyalgia through group exercises, which are dynamic, smooth and aim functionality. Each session consists of 60 minutes with 3 parts: initial warming up time, main part through games, group dynamics and pure aerobic workout, and final cool down with stretching. This exercise is done to the rhythm of melodic music, adapted to the tastes of the participants and also adapted on the way to perform the exercise. For this, they were shown a list of 100 music compositions from which participants choose a minimum of 20 preferences. All exercises are performed with proper postural control both dissociated and global and within a framework of therapeutic proprioceptive gymnastics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-impact aerobic exercise
Description: Low-impact aerobic exercise. Then intervention is like the previous group but with the difference that physical activity is not performed to the rhythm of chosen melodic music. Therefore, exercises are done with general chill-out music throughout the session, without adaptation of the exercise to the music.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: With this group no intervention is done, but they are assessed like the other groups.
Study: NCT01605708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN846
Description: Dose 1
Study: NCT01383356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Single Tablet
Description: Metformin medium doseTablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin Combo
Description: Fixed dose combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin Single Tablet
Description: Linagliptin Single medium dose Tablet
Study: NCT00956319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem MR
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estazolam
Description: oral
Study: NCT03386383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Individual session, physical activity tracker, online intervention
Study: NCT03170596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tazarotene gel 0.1%
Description: Patients will be instructed to apply 0.1% tazarotene gel as a thin film over the affected area once daily in the evening.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microneedling
Description: Microneedling is a method of percutaneous collagen induction
Study: NCT00960882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMMET-01
Description: 1050.6 mg daily for 30 days
Study: NCT03119987

Intervention type: DIAGNOSTIC_TEST
Intervention: Red cell distribution widths
Description: Measured value of Red cell distribution widths in initial laboratory result of blood cell counts at emergency department
Study: NCT02796599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation during exercise with facial or nasal mask.
Description: Every patients will achieve 3 constant work load test (CWLT) at 75% Wpic. The first CWLT will be realized without any ventilatory support. The 2 others CWLT will be achieved with non-invasive ventilation support using facial or nasal interface in a randomized order.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation during exercise with facial or nasal mask.
Description: Every patients will achieve 3 constant work load test (CWLT) at 75% Wpic. The first CWLT will be realized without any ventilatory support. The 2 others CWLT will be achieved with non-invasive ventilation support using facial or nasal interface in a randomized order.
Study: NCT00494728

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking Cessation Treatment
Description: 12 60-minute individual sessions of standard smoking cessation treatment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking Cessation Treatment
Description: 12 60-minute individual sessions of standard smoking cessation treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine Replacement Therapy
Description: 21 mg patch for 4 weeks; 14 mg patch for 2 weeks; 7 mg patch for 2 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine Replacement Therapy
Description: 21 mg patch for 4 weeks; 14 mg patch for 2 weeks; 7 mg patch for 2 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBASP
Description: Individual counseling sessions where taught/develop interpersonal and behavioral coping skills to help decrease depression and negative moods, and to increase ability to quit smoking.
Study: NCT02855970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: completion of a quality of life questionnaire
Study: NCT00790465

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dark chocolate
Description: 21 g/d of dark chocolate for 2 weeks (7 g. before each meal). 7 grams of dark chocolate at day 1 during manometry.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: placebo chocolate with crossover to dark chocolate
Description: Placebo at day 1 during manometry, and than crossover to dark chocolate for 2 weeks treatment.
Study: NCT01729143

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour energy expenditure and substrate utilization
Description: Subjects spent two x 24-hour periods inside the metabolic chamber at the UNC NRI (black pepper and no pepper control) each separated by one week. Subjects were requested to arrive at the study center each morning in a fasted state (at least 10 hours). During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements. Study meals (with the exception of the 1.5g of black pepper) were identical between the black pepper and no pepper control study days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 24-hour energy expenditure and substrate utilization
Description: Subjects spent two x 24-hour periods inside the metabolic chamber at the UNC NRI (black pepper and no pepper control) each separated by one week. Subjects were requested to arrive at the study center each morning in a fasted state (at least 10 hours). During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements. Study meals (with the exception of the 1.5g of black pepper) were identical between the black pepper and no pepper control study days.
Study: NCT02736604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitrous oxide anesthesia
Description: General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with Nitrous Oxide and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: air anesthesia
Description: General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with air and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngeal mask airway (LMA Supreme Size 3/4

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngeal mask airway (LMA Supreme Size 3/4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Study: NCT06020807

Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder EpiCheck
Description: Bladder EpiCheckTM (EpiCheck) is a urine test for monitoring of recurrence of NMIBC based on analysis of 15 informative DNA methylation biomarkers.
Study: NCT01744977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: packaging
Description: Intervention provides usual statin medication dispensed in pre-prepared adherence packaging (blister packaging) rather than the previously received prescription bottles
Study: NCT05647239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shotblocker
Description: Shotblocker is a small plastic tool that can be used in all age groups in reducing pain due to injection, is non-medicinal, non-invasive, easy to use, and inexpensive and does not require material preparation
Study: NCT03772158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine 10mg
Description: Chewable tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine 10mg
Description: Chewable tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine 10mg
Description: Chewable tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine 10 mg
Description: Immediate Release Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine 10 mg
Description: Immediate Release Tablet
Study: NCT03496584

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate Juice
Description: After the one week run-in period of consuming an ellagitannin-free diet, participants will undergo the skin testing followed by the postprandial meal test with a high fat (HF) test meal consumed with the first dose of the intervention (Pom J or placebo). For the next 12 weeks, participants will consume a daily dose of pomegranate juice 1x/day. During week 4 participants will undergo another skin testing. During week 12 participants will undergo another skin testing and postprandial meal challenge. Stool will be collected at week 1, 4 and 12.
Study: NCT01087463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantum
Description: Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
Study: NCT03496584

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Juice
Description: After the one week run-in period of consuming an ellagitannin-free diet, participants will undergo the skin testing followed by the postprandial meal test with a high fat (HF) test meal consumed with the first dose of the intervention (Pom J or placebo). For the next 12 weeks, participants will consume a daily dose of placebo juice 1x/day. During week 4 participants will undergo another skin testing. During week 12 participants will undergo another skin testing and postprandial meal challenge. Stool will be collected at week 1, 4 and 12.
Study: NCT02480257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TARA
Description: The intervention consists of four 3-week modules: 1. Autonomic regulation: Learning and practicing the ability to create a calm and safe inner state through breathing exercises and movement/physical activity. 2. Interoceptive awareness: Attention training, targeting external stimuli then sensory stimuli using short body scan exercises and guided meditations. 3.Emotion regulation: Recognizing, labeling, externalizing, and befriending emotions. 4. Metacognition, core-values, and committed action: Understanding social triggers to negative emotions and experiential avoidance strategies and their impact on obtaining desired life-goals. Home practice of TARA skills is encouraged, with breathing instructions and short, guided meditations provided via audio tracks.
Study: NCT04277897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepenofovir Fumarate Tablets Single Dose
Description: Oral Tablet; Subjects will receive either a single dose of Hepenofovir Fumarate Tablets on Day 1 only (SAD), once daily dosing of HTS starting on Day 1 through Day 7 (MAD).
Study: NCT02201589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular repair with Valiant PS-IDE Stent Graft
Description: Endovascular stent graft repair of lesions in the ascending thoracic aorta using the Medtronic Valiant PS-IDE (Physician Sponsored-Investigational Device Exemption) Stent Graft System with the Captivia Delivery System
Study: NCT01133951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OAC triple therapy
Description: Omeprazole, 20mg, amoxicillin, 1000mg, and clarithromycin, 500mg, all twice a day for 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Omeprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 2 weeks.
Study: NCT00914160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)
Study: NCT04277897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepenofovir Fumarate Tablets Single Dose
Description: Oral Tablet; Subjects will receive either a single dose of Hepenofovir Fumarate Tablets on Day 1 only (SAD), once daily dosing of HTS starting on Day 1 through Day 7 (MAD).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match Hepenofovir Fumarate Tablets
Study: NCT00914160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)
Study: NCT04277897

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match Hepenofovir Fumarate Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepenofovir Fumarate Tablets Dose4
Description: Oral Tabet; Subjects will receive Hepenofovir Fumarate Tablets Dose4 on Day 1 in fast condition, then receive Hepenofovir Fumarate Tablets Dose4 on Day 8 in fed condition.
Study: NCT01101867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspart fixed dose
Description: fixed dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspart flexible dose
Description: dose based upon carbohydrate intake and total daily requirements
Study: NCT01807988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT
Description: Internetbased cognitive behavior therapy (iCBT) contains interventions that will help the participant to change her behavior to experience more positive reinforcement in daily life and also to challenge her negative patterns of thought. There are also information and exercices to improve sleep, increase physical activity, train mindfulness, handle anxiety and to learn about depression.
Study: NCT00914160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
Study: NCT03883425

Intervention type: OTHER
Intervention: interRAI-HC assessments
Description: Standardized geriatric assessments done with the interRAI-HC instrument (Canadian French version 9.1) by trained nurses

Intervention type: OTHER
Intervention: interRAI-HC assessments
Description: Standardized geriatric assessments done with the interRAI-HC instrument (Canadian French version 9.1) by trained nurses

Intervention type: OTHER
Intervention: interRAI-HC assessments
Description: Standardized geriatric assessments done with the interRAI-HC instrument (Canadian French version 9.1) by trained nurses